Latest Articles
31. 07. 2020
List of reimbursed medicinal products valid as of 1.8.2020
Acting in compliance with Section 39n(1) of Act No. 48/1997 Coll., on Public Health Insurance, as amended (“Act”), the State Institute for Drug Control publishes the List of...
17. 07. 2020
Questions and Answers on the Use of Advanced Therapy Medicinal Products with Out-of-Specification Release Test Results
State Institute for Drug Control issues Questions and Answers document to clarify possibility of administration of advanced therapy medicinal products (ATMPs) in case...
30. 06. 2020
List of reimbursed medicinal products valid as of 1.7.2020
Acting in compliance with Section 39n(1) of Act No. 48/1997 Coll., on Public Health Insurance, as amended (“Act”), the State Institute for Drug Control publishes the List of...
29. 05. 2020
List of reimbursed medicinal products valid as of 1.6.2020
Acting in compliance with Section 39n(1) of Act No. 48/1997 Coll., on Public Health Insurance, as amended (“Act”), the State Institute for Drug Control publishes the List of...
14. 05. 2020
Opinion of SÚKL's Department of Clinical Trials on Medicinal Products on Ongoing Clinical Trials and To-Be-Commenced Clinical Trials in Light of the COVID-19 Epidemiological Situation of 25 June 2020
superseding opinions of 14 May 2020; added 1 July 2020
13. 05. 2020
HOME CARE
Conditions under which it will be possible to include “ Home Care ” into the conduct of clinical trials also outside the period of COVID-19 pandemics.
12. 05. 2020
Brexit – on 7 May 2020, the European Commission published an updated notice to stakeholders
„WITHDRAWAL OF THE UNITED KINGDOM AND EU RULES IN THE FIELD OF CLINICAL TRIALS“
05. 05. 2020
SÚKL is involved in Simultaneous National Scientific Advice (SNSA) Pilot Project
EU-Innovation Network, who`s member is also State Institute for Drug Control (SÚKL), announced launch of Simultaneous National Scientific Advice (SNSA) Pilot Project. SÚKL...
cz
